Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

The Effect of Triflusal on Peripheral Microcirculation Dysfunction

Phase 4
Completed
Conditions
Interventions
First Posted Date
2012-06-05
Last Posted Date
2014-03-05
Lead Sponsor
Yonsei University
Target Recruit Count
92
Registration Number
NCT01612273
Locations
🇰🇷

Division of Cardiology, Department of Internal Medicine, severance hospital, Seoul, Korea, Republic of

The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency

First Posted Date
2012-05-15
Last Posted Date
2012-05-15
Lead Sponsor
Prince Sultan Cardiac Center, Adult Cardiology Department.
Target Recruit Count
200
Registration Number
NCT01598337
Locations
🇸🇦

Prince Sultan Cardiac Center, Riyadh, Saudi Arabia

PROMUS Element Plus US Post-Approval Study

First Posted Date
2012-05-02
Last Posted Date
2018-07-26
Lead Sponsor
Boston Scientific Corporation
Target Recruit Count
2681
Registration Number
NCT01589978
Locations
🇺🇸

Community Heart and Vascular Hospital, Indianapolis, Indiana, United States

🇺🇸

North Memorial Medical Center, Minneapolis, Minnesota, United States

🇺🇸

IU Health North Medical Center, Carmel, Indiana, United States

and more 49 locations

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

First Posted Date
2012-04-02
Last Posted Date
2016-06-13
Lead Sponsor
Biogen
Target Recruit Count
173
Registration Number
NCT01568112
Locations
🇺🇸

Research Site, St Paul, Minnesota, United States

Aspirin Versus Aspirin + ClopidogRel Following Transcatheter Aortic Valve Implantation: the ARTE Trial

First Posted Date
2012-03-21
Last Posted Date
2017-05-11
Lead Sponsor
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Target Recruit Count
178
Registration Number
NCT01559298
Locations
🇨🇦

St-Paul's Hospital, Vancouver, British Columbia, Canada

🇨🇦

IUCPQ, Quebec, Canada

Early Prevention of Preeclampsia Study

Not Applicable
Terminated
Conditions
Interventions
First Posted Date
2012-03-07
Last Posted Date
2018-06-29
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
104
Registration Number
NCT01547390
Locations
🇺🇸

Washington University, Saint Louis, Missouri, United States

Aspirin Withdrawal in Non-ischaemic Cardiomyopathy Study

Phase 4
Completed
Conditions
Interventions
First Posted Date
2012-02-16
Last Posted Date
2016-06-01
Lead Sponsor
The Alfred
Target Recruit Count
12
Registration Number
NCT01534026
Locations
🇦🇺

The Alfred Hospital, Melbourne, Victoria, Australia

Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke

First Posted Date
2012-01-25
Last Posted Date
2012-01-25
Lead Sponsor
Zhejiang Hospital
Target Recruit Count
40
Registration Number
NCT01518231
Locations
🇨🇳

Yaguo Li, Hangzhou, Zhejiang, China

PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)

First Posted Date
2012-01-16
Last Posted Date
2019-03-26
Lead Sponsor
Boston Scientific Corporation
Target Recruit Count
22
Registration Number
NCT01510327
Locations
🇯🇵

Saiseikai Yokohama-City Eastern Hospital, Yokohama City, Kanagawa-ken, Japan

🇯🇵

Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo-to, Japan

🇯🇵

Sakakibara Heart Institute, Japan Research Promotion Society for Cardiovascular Diseases, Fuchu-shi, Tokyo, Japan

and more 2 locations

LIPS-A: Lung Injury Prevention Study With Aspirin

First Posted Date
2012-01-06
Last Posted Date
2017-03-06
Lead Sponsor
Mayo Clinic
Target Recruit Count
400
Registration Number
NCT01504867
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

🇺🇸

Bridgeport Hospital, Bridgeport, Connecticut, United States

and more 13 locations
© Copyright 2024. All Rights Reserved by MedPath